tradingkey.logo
tradingkey.logo
Search

Pediatrix Medical Group Inc

MD
Add to Watchlist
23.610USD
+0.045+0.19%
Close 06/18, 16:00ETQuotes delayed by 15 min
2.03BMarket Cap
11.31P/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
7.14
Change
0
The current earnings forecast score of Pediatrix Medical Group Inc is 7.14, ranking 46 out of 76 in the Healthcare Providers & Services industry. The average price target is 22.00, with a high of 26.00 and a low of 21.00.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
23.167
Target Price
-1.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

68
Total
8
Median
9
Average
Company name
Ratings
Analysts
Pediatrix Medical Group Inc
MD
7
CVS Health Corp
CVS
29
Teladoc Health Inc
TDOC
27
HCA Healthcare Inc
HCA
26
Natera Inc
NTRA
23
Tenet Healthcare Corp
THC
23
1
2
3
...
14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Pediatrix Medical Group Inc's expected revenue for the next quarter?

Pediatrix Medical Group Inc's expected revenue is 478.45M.

What is Pediatrix Medical Group Inc's price target?

Analysts forecast that Pediatrix Medical Group Inc's price target is USD 22.00, with the highest forecast at USD 26.00 and the lowest forecast at USD 21.00.

How have Pediatrix Medical Group IncMD's recent earnings per share performed?

The market expectation was USD 0.37, while Pediatrix Medical Group IncMD's earnings per share (EPS) for the previous quarter was USD 0.41. EPS for the next quarter is expected at USD 0.59.

What is the analyst rating for Pediatrix Medical Group Inc?

Based on the ratings of Pediatrix Medical Group Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI